Risk of radiation pneumonitis in patients with emphysema after stereotactic body radiotherapy for non-small cell lung cancer assessed by quantitative CT.
emphysema
lung cancer
non-small cell lung cancer
quantitative CT value
radiation pneumonitis
stereotactic body radiotherapy
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
28
11
2019
accepted:
25
05
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
6
8
2020
Statut:
ppublish
Résumé
Quantitative CT assessment of patients with pulmonary emphysema is used to measure pulmonary function. The present study evaluated whether the quantitative CT value can accurately estimate the risk of radiation pneumonitis (RP) after stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) in patients with and without emphysema. A total of 80 patients with stage I NSCLC receiving SBRT at a dose of 50 or 60 Gy in five fractions at our hospital between November 2003 and October 2015 were included in the analysis. A total of 33 (41%) patients were diagnosed with emphysema on CT examination. Dosimetric parameters, quantitative CT percentage value of low attenuation area (LAA%) in the whole lung, and average whole lung CT density values were used to examine the risk of RP. Among the 80 patients, 26 (33%) and 3 (4%) experienced Grade 1 and Grade 2 RP, respectively, during the median observation period of 18.8 (1.8-106.8) months. The RP rate for patients with a LAA% (<-910 HU) of ≤25% was significantly higher than that of subjects with LAA% (<-910 HU) >25% (P=0.037). The RP rate in subjects with an average HU value of >-790 HU was significantly higher compared with that of patients with ≤-790 HU (P=0.036). Age (hazard ratio [HR]=2.46; P=0.03) and average HU (HR=3.39; P=0.02) were significantly associated with RP, whereas mean lung dose was not identified to be significant in multivariate analysis. The quantitative CT value was associated with RP after SBRT.
Identifiants
pubmed: 32754317
doi: 10.3892/mco.2020.2073
pii: MCO-0-0-02073
pmc: PMC7393626
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3Informations de copyright
Copyright © 2020, Spandidos Publications.
Références
Lancet. 1984 Aug 11;2(8398):320-2
pubmed: 6146866
Chest. 2012 Apr;141(4):858-866
pubmed: 21885726
Am J Respir Crit Care Med. 1995 Aug;152(2):653-7
pubmed: 7633722
Lung Cancer. 2010 Jul;69(1):77-85
pubmed: 19910075
Br J Radiol. 2015 Feb;88(1046):20140596
pubmed: 25490255
Lung. 2013 Dec;191(6):585-91
pubmed: 24085320
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1357-1366
pubmed: 27325482
PLoS One. 2014 Jun 26;9(6):e100994
pubmed: 24967586
Am J Respir Crit Care Med. 2015 Feb 1;191(3):285-91
pubmed: 25522175
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1149-56
pubmed: 21640513
Br J Radiol. 2018 Jul;91(1087):20170921
pubmed: 29651875
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):190-5
pubmed: 22929858
AJR Am J Roentgenol. 2013 Sep;201(3):W460-70
pubmed: 23971478
Clin Lung Cancer. 2018 Jan;19(1):e85-e90
pubmed: 28655592
Chest. 2014 Feb;145(2):346-353
pubmed: 24008835
Radiology. 2010 Oct;257(1):260-8
pubmed: 20663967
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):457-62
pubmed: 21035956
Radiother Oncol. 2016 Oct;121(1):1-8
pubmed: 27600155
Chest. 1988 Oct;94(4):782-7
pubmed: 3168574
Radiother Oncol. 2010 Jan;94(1):1-11
pubmed: 20074823
Chest. 2013 May;143(5 Suppl):e166S-e190S
pubmed: 23649437
N Engl J Med. 2011 Mar 10;364(10):897-906
pubmed: 21388308
Invest Radiol. 1993 Mar;28(3):242-6
pubmed: 8486491
J Comput Assist Tomogr. 2015 Mar-Apr;39(2):171-5
pubmed: 25474145
Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):483-91
pubmed: 16904838